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Objective: to establish whether deletion of the angiotensin-converting enzyme (ACE) gene is a risk factor predisposing
to abdominal aortic aneurysm (AAA) or not.
Methods: the study included 125 patients with AAA and 153 controls randomly selected from 328 individuals. The
control subjects were confirmed not to have an AAA, but matched with the AAA group for age, sex, hypertension,
diabetes mellitus, and hyperlipidaemia. The presence of ACE polymorphism was detected by a polymerase chain reaction
using DNA extracted from blood.
Results: the distribution of ACE genotypes and allele frequencies in the control and AAA groups was not significantly
different.
Conclusion: the deletion polymorphism in the ACE gene is not a risk factor for AAA.
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Introduction correlation between deletion polymorphism in the
ACE gene and aortic aneurysm has been carried out.
Inflammatory processes1 and proteases such as Previous studies have focused on occlusive ath-
erosclerotic disease rather than aneurysmal disease.metalloproteinase2 have been reported as causes of
aortic aneurysm, but their mechanism of action Although it is well known that atherosclerosis con-
tributes to the formation of aortic aneurysm,3 otherremains unknown. Atherosclerosis of the aortic wall
underlies the pathogenesis of aortic aneurysm3 and factors are probably involved, e.g. hypertension. As
ACE polymorphism has been related to a variation innumerous studies4–6 concerning the risk factors for
aortic aneurysm have been published. the plasma levels of the enzyme,16 it could be associated
with aortic aneurysms. In this study we examinedA number of recent studies have focused on the
relationship between deletion polymorphism in the whether deletion polymorphism in the ACE gene is a
risk factor predisposing to aortic aneurysm or not.angiotensin-converting enzyme (ACE) gene and
cardiovascular diseases.7–14 One type of ACE gene
polymorphism is created by the insertion (I allele) or
deletion (D allele) of a 287-base-pair (bp) DNA
Materials and Methodssequence within intron 16.15 While many reports have
demonstrated a positive correlation between the de-
Study protocolletion of the ACE gene (D) and cardiovascular diseases,
such as restenosis after emergency coronary angio- Data concerning age, sex, body mass index, hyper-plasty,9 cardiac hypertrophy and remodelling,10,11 tension, diabetes mellitus, and hyperlipidaemia wereatheromatous renal artery stenosis,12 and lacunar collected from patients with AAA. As a control group,stroke,13 to our knowledge no study examining the volunteers matched for age, sex, body mass index,
hypertension, diabetes mellitus, and hyperlipidaemia
* Please address all correspondence to: K. Hamano, First Department were selected from a database. The ACE genotype wasof Surgery, Yamaguchi University School of Medicine, Ube, Yama-
guchi, 755-8505, Japan. determined using DNA extracted from blood. Blood
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Table 1. Subject characteristics. Detection of ACE polymorphism
Control AAA DNA was extracted from 10 ml whole blood usingParameter (n=153) (n=125) p
SepaGene (Sanko Junyaku Co., Tokyo, Japan). A poly-
Age (y.o.) 67.2–0.9 68.7–0.9 n.s. merase chain reaction (PCR) was performed according
Sex (% male) 54 60 n.s. to the methods of Tiret et al.17 with minor modification.BMI (kg/m2) 22.0–0.2 21.7–0.3 n.s.
Hypertension (%) 61 53 n.s. The sequences of the sense and antisense primers were
Diabetes mellitus (%) 5 4 n.s. 5-CTG GAG ACC ACT CCC ATC CTT TCT-3 and
Hyperlipidaemia (%) 12 10 n.s. 5-GAT GTG GCC ATC ACA TTC GTC AGA T-3,
AAA: abdominal aortic aneurysm; BMI: body mass index. respectively. PCR was performed in a final volume of
50 ll that contained 100 ng genomic DNA, 20 pmol of
each primer, 250 lmol/l of each of the four dNTPs,
3.0 mmol MgCl, 50 mmol KCl, 10 mmol/l Tris-HCl at
samples from the AAA patients and the control sub- pH 8.4, and 0.4 U Taq polymerase. Amplification was
jects were performed after informed consent had been carried out in the DNA Thermal Cycler PJ 2000 for 30
obtained. This clinical study was approved by the cycles with steps of denaturation at 94 °C for 1 min,
Medical Ethics Committee of the Yamaguchi Uni- annealing at 55 °C for 1 min, and extension at 72 °C
versity School of Medicine. Data concerning hyper- for 1 min. The PCR products were subjected to electro-
tension, diabetes mellitus, and hyperlipidaemia were phoresis in 1.5% agarose gel, after which the DNA
collected from medical records or interview. The defin- was visualised directly by ethidium bromide staining.
ition of hypertension in this study was either a need Because the D allele in heterozygous samples is
for antihypertensive agents or a resting blood pressure preferentially amplified 30 cycles, each sample found
of more than 160/95 mmHg. Diabetes mellitus was to have the DD genotype was subjected to a second,
defined as either a need for drugs or insulin to control independent PCR amplification with a primer pair
blood glucose, or a fasting blood glucose of more than that recognises an insertion-specific sequence (hace5a,
7.7 mmol/l. Hyperlipidaemia was defined as either a 5-TGG GAC CAC AGC GCC CGC CAC TAC-3 and
need for drugs to control blood cholesterol and/or tri- hace5c, 5-TCG CCA GCC CTC CCA TGC CCA TAA-3),
glyceride, a total cholesterol of more than 62.4 mmol/l, with identical PCR conditions except for an annealing
or triglyceride of more than 3.42 mmol/l. temperature of 67 °C.17 The reaction yields a 335-bp
amplicon only in the presence of an I allele, and no
product in the samples was homozygous for DD.
Subjects
Statistical analysis
A total of 125 patients who underwent operations for
AAA and were followed up at Yamaguchi University Allele frequencies were deduced from genotype fre-
Hospital or related hospitals were randomly chosen quencies, and the difference between the groups was
from 344 AAA patients. The ages of the patients were assessed by the Chi-squared test. The values of clinical
expressed as those when the patients initially visited characteristics except for age were also assessed by
the hospitals. the Chi-squared test. Age was expressed as the
A total of 153 control subjects without cardiovascular mean–s.e.m. and compared using ANOVA (StatView
disease – but matching the AAA group for age, sex, Ver 4.02). No evidence of significant deviations from
history of hypertension, diabetes mellitus, and hyper- the Hardy–Weinberg equilibrium was found in these
lipidaemia – were randomly selected from among 328 samples.
subjects attending for voluntary health screening or
because of transient non-cardiovascular symptoms.
None of the 153 control subjects had any evidence of
an aortic aneurysm, measured usually by computed Results
tomography.
The characteristics of participants are shown in Table The ACE-ID genotype was found in 70 subjects (46%)
from the control group and 48 patients (38%) from the1. There were no significant differences between the
two groups in terms of age, sex, body mass index, AAA group. The ACE-DD genotype was found in 29
subjects (19%) from the control group and 26 patientshypertension, diabetes mellitus, or hyperlipidaemia.
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Table 2. Distribution of ACE genotypes and allele frequencies in correlation between deletion of the ACE gene and
the control and abdominal aortic aneurysm groups. AAA. We therefore conclude that deletion of the ACE
gene is not a risk factor predisposing to the formationControl AAA
(n=153) (n=125) of an AAA.
Several papers have reported that the ACE genotype
n % n % showed no association with myocardial infarction8,18 or
Genotype ventricular hypertrophy.32 Several explanations have
II 54 35 51 41 been proposed to account for these differences: one
ID 70 46 48 38 being that previously reported positive studies wereDD 29 19 26 21
p=0.418 based on inadequate sample size, and another being
Allele frequency that the ACE-D allele frequency varies among races.
I 124 58 99 60 However, this matter is still controversial. In our studyD 99 42 74 40
p=0.774 32 (25.6%) AAA patients attended with ischaemic heart
disease, which means that they have either a history of
AAA: abdominal aortic aneurysm. old myocardial infarction or a newly found ischaemic
change on electrocardiogram (ECG) at rest or exercise
at admission. On the other hand, there was no specific(21%) from the AAA group. There were no significant
change on ECG in the control subjects.differences among the three types of genotype between
the control and AAA groups (p=0.418). Furthermore,
the allele frequency of D was 0.42 and 0.40 in the
control and AAA groups, respectively. No significant Acknowledgements
differences in the allele frequency were seen between
The authors would like to express their gratitude to doctors fromthe control and AAA groups (p=0.774).
the following hospitals affiliated with Yamaguchi University for
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